阿德福韦酯联合扶正化瘀胶囊治疗慢性乙型病毒性肝炎肝纤维化临床观察  

The clinical observation of adefovir dipivoxil combined Fuzhenghuayu capsule treatment of chronic hepatitis B with liver fibrosis

作　　者：郑金莉[1] 周岳进[1] 肖扬[1] 卢成鸿[1] 潘华将[1] 胡侠[1] 胡操寒[1] 

机构地区：[1]解放军第一一八医院肝病科,浙江温州325000

出　　处：《实用临床医药杂志》2011年第3期63-64,70,共3页Journal of Clinical Medicine in Practice

摘　　要：目的探讨阿德福韦酯联合扶正化瘀胶囊对慢性乙型病毒性肝炎肝纤维化指标的影响。方法 70例慢性乙型病毒性肝炎患者被随机分为联合治疗组(n=35,阿德福韦酯联合扶正化瘀胶囊)和对照组(n=35,单用阿德福韦酯),临床观察48周疗效。结果联合治疗组患者48周后肝纤维化指标下降幅度明显高于对照组(P<0.05);联合治疗组48周时脾脏厚度恢复正常,门静脉内径明显缩小,与治疗前比较,差异均有显著性意义(P<0.05);其中48周时联合治疗组与单药治疗组比较,差异有显著性意义(P<0.05)。结论 阿德福韦酯联合扶正化瘀胶囊治疗肝纤维化疗效优于单药阿德福韦酯治疗。Objective To explore the effect of Fuzhenghuayu capsule combined adefovir dipivoxil on liver fibrosis in chronic hepatitis B.Methods Seventy patients with chronic hepatitis B patients were randomly divided into combined treatment group（n=35,adefovir dipivoxil combined Fuzhenghuayu capsule） and the control group（n=35,Adefovir dipivoxil alone）.Clinical efficacy was observed 48 weeks later.Results After 48 weeks,liver fibrosis indexs in the treatment group was significantly lower than control group（P〈0.05）.Before treatment,spleen returned to normal thickness,portal vein diameter significantly reduced in treatment group,the differences were significant（P〈0.05）.Conclusion Fuzhenghuayu capsule combind adefovir dipivoxil was effective on liver fibrosis in chronic hepatitis B.

关 键 词：阿德福韦酯 扶正化瘀胶囊 肝纤维化 联合治疗 

分 类 号：R575.2[医药卫生—消化系统]